Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs.

Literature DB >> 15711912

Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs.

David L Kleinberg¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 15711912 DOI： 10.1007/s11154-005-5222-2

Source DB: PubMed Journal: Rev Endocr Metab Disord ISSN： 1389-9155 Impact factor: 6.514

× No keyword cloud information.

40 in total

1. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors: A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal: J Clin Endocrinol Metab Date: 2001-06 Impact factor: 5.958

2. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors: I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal: J Clin Invest Date: 1997-11-01 Impact factor: 14.808

3. Sandostatin LAR in acromegalic patients: long-term treatment.

Authors: A K Fløgstad; J Halse; S Bakke; I Lancranjan; P Marbach; C Bruns; J Jervell
Journal: J Clin Endocrinol Metab Date: 1997-01 Impact factor: 5.958

4. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.

Authors: J P Tauber; T Babin; M T Tauber; F Vigoni; A Bonafe; M Ducasse; A G Harris; F Bayard
Journal: J Clin Endocrinol Metab Date: 1989-05 Impact factor: 5.958

5. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

Authors: P Lundin; B Edén Engström; F A Karlsson; P Burman
Journal: AJNR Am J Neuroradiol Date: 1997-04 Impact factor: 3.825

6. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.

Authors: Gisbert Weckbecker; Ulrich Briner; Ian Lewis; Christian Bruns
Journal: Endocrinology Date: 2002-10 Impact factor: 4.736

Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs.

1. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

2. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

3. Sandostatin LAR in acromegalic patients: long-term treatment.

4. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.

5. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

6. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.

7. Improvement of acromegaly after octreotide LAR treatment.

8. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.

9. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide.

10. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Review 1. Treatment of pituitary tumors: surgery.

2. A structural and functional acromegaly classification.

Review 3. The role of somatostatin analogs in Cushing's disease.

Review 4. From somatostatin to octreotide LAR: evolution of a somatostatin analogue.

Review 5. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Review 6. Pasireotide: a novel treatment for patients with acromegaly.